Compare YELP & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YELP | ARDX |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | United States |
| Employees | 5168 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2011 | 2014 |
| Metric | YELP | ARDX |
|---|---|---|
| Price | $21.85 | $6.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $29.17 | $15.14 |
| AVG Volume (30 Days) | 1.2M | ★ 4.0M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.15 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $1,464,955,000.00 | $2,607,000.00 |
| Revenue This Year | $2.19 | $37.75 |
| Revenue Next Year | $2.34 | $34.24 |
| P/E Ratio | $74.80 | ★ N/A |
| Revenue Growth | ★ 3.75 | N/A |
| 52 Week Low | $19.60 | $3.54 |
| 52 Week High | $39.58 | $8.40 |
| Indicator | YELP | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 32.74 | 49.42 |
| Support Level | $19.60 | $5.54 |
| Resistance Level | $25.09 | $6.70 |
| Average True Range (ATR) | 1.34 | 0.32 |
| MACD | -0.57 | -0.07 |
| Stochastic Oscillator | 12.24 | 22.86 |
Yelp Inc operates in the online content market based in the United States. It provides a web-based platform and mobile application to bridge the gap between businesses and consumers. The platform assists consumers through product reviews, tips, photos and videos thereby enabling them in making appropriate buying decisions and posting their feedbacks. Its products and services includes Advertising Products and Business Page Products. In addition, it also lets the buyers directly transact with businesses directly through its platform. Yelp generates revenue mainly from the sale of advertising on its website and mobile app to businesses. The company generates majority of the revenue from United States, and also has its presence in other countries.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.